20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Faeth Therapeutics, Inc. (FTH) operates in the BIOTECHNOLOGY industry and is headquartered in Rockville, United States with about 29 employees. Its market capitalization is roughly $891 million. In the fiscal year ended 2025-12-31, FTH reported $0M in revenue and ($21M) in net income.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ($5M) | $0M | $0M | $0M | $0M | — | — | — | — |
| Gross Profit | — | — | ($1M) | ($1M) | ($2M) | ($1M) | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($199M) | ($22M) | ($32M) | ($37M) | ($49M) | ($37M) | ($19M) | ($12M) | ($13M) |
| Operating Margin % | 4098.5% | — | — | — | — | — | — | — | — |
| Net Income | ($196M) | ($21M) | ($30M) | ($34M) | ($49M) | ($37M) | ($20M) | ($17M) | ($13M) |
| Net Margin % | 4030.7% | — | — | — | — | — | — | — | — |
| EBITDA | ($195M) | ($21M) | ($30M) | ($33M) | ($47M) | ($35M) | ($18M) | ($14M) | ($13M) |
| Earnings Per Share (EPS) | $-141.65 | $-16.72 | $-24.01 | $-24.40 | $-31.65 | $-26.56 | $-13.14 | $-11.42 | $-8.89 |
| Shares Outstanding (M) | — | 1M | 1M | 1M | 2M | 1M | 2M | 1M | 1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | ($5M) | $0M | $0M | — | — |
| Gross Profit | — | ($133M) | — | — | — | — | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($18M) | ($171M) | ($5M) | ($5M) | ($5M) | ($7M) | ($7M) | ($8M) |
| Operating Margin % | — | — | — | 100.0% | — | — | — | — |
| Net Income | ($16M) | ($170M) | ($5M) | ($5M) | ($5M) | ($7M) | ($8M) | ($7M) |
| Net Margin % | — | — | — | 94.2% | — | — | — | — |
| EBITDA | ($16M) | ($170M) | ($5M) | ($5M) | ($5M) | ($7M) | ($8M) | ($7M) |
| Earnings Per Share (EPS) | $-2.84 | $-131.45 | $-3.74 | $-3.62 | $-3.91 | $-5.45 | $-6.18 | $-5.77 |
| Shares Outstanding (M) | — | 1M | 1M | 1M | 1M | 1M | 1M | 1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($34M) | ($20M) | ($25M) | ($32M) | ($39M) | ($30M) | ($18M) | ($9M) | ($10M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $2M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($34M) | ($20M) | ($25M) | ($32M) | ($39M) | ($32M) | ($19M) | ($9M) | ($10M) |
| FCF Margin % | 698.2% | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($16M) | ($11M) | ($4M) | ($4M) | ($6M) | ($7M) | ($6M) | ($5M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($16M) | ($11M) | ($4M) | ($4M) | ($6M) | ($7M) | ($6M) | ($5M) |
| FCF Margin % | — | — | — | 73.9% | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $189M | $23M | $45M | $74M | $118M | $153M | $21M | $1M | $2M |
| Cash & Cash Equivalents | $27M | $9M | $10M | $13M | $18M | $7M | $17M | $0M | $1M |
| Total Liabilities | $16M | $4M | $7M | $9M | $15M | $7M | $6M | $70M | $55M |
| Total Debt (Short + Long-Term) | $1M | $1M | $2M | $2M | $2M | $1M | $0M | $16M | $1M |
| Total Shareholders' Equity | $173M | $19M | $38M | $65M | $103M | $147M | $16M | ($69M) | ($53M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive FTH viewer.
About TickerBase · Data methodology & sources · Privacy · Terms